Cybin Corp updates investors on its IP development
New Psychedelics ETF Is Another Sector Milestone
The new Horizons Psychedelic Stock Index ETF will add new demand and increased visibility for psychedelic drug stocks.
Legal Psychedelic Therapy Comes to Alberta With Ground-Breaking Health Canada Decision
Health Canada issues its first Section 56 Exemption for psilocybin use to an Alberta resident.
Joe Rogan And Tim Ferriss Drive Attention To Benefits Of Psychedelics
Two of the most powerful voices in new media are advocating for the mental health benefits of psychedelics in a big way.
Capital, Compounds and Clinics: Why 2021 Will Be A Stellar Year For Psychedelic Stocks
After a great year in 2020, psychedelic drug stocks are poised for an even better year in 2021.
Will Psychedelic Stocks Be The New ESG Favorites For 2021?
Psychedelic drugs have the potential to revolutionize mental health care while simultaneously saving the global economy $100s of billions each year.
How Psychedelic Drug Stocks Took Off in 2020
After some early turbulence in 2020, psychedelic drug stocks have taken off.
MindMed Upsizes Previously Announced CAD $50m Bought Deal Public Offering
MindMed increases its latest bought-deal financing to CAD$80 million.
Numinus Wellness : Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming
Numinus acquires a Montreal-based provider of psychedelic-assisted psychotherapies.
MindMed Announces $50 Million Bought Deal Public Offering
MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers
Eleusis acquires a ketamine therapy provider and announces a new R&D program.
